Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD LSEG Data AD CME Group Education AD Bank of England Statistics AD Investing.com Markets
Venues & MTFs

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

By Nasdaq Market Structure

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.

Read at source

Read also
  1. Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial
  2. Larimar Therapeutics Names John Harlow As President And COO
  3. Did You Miss Out on Nvidia and Micron Technology? This Super Semiconductor Stock Could Soar Over the Next Few Years.
  4. Higher Crude Oil Prices, Weak Economic Data Weigh On French Stocks
  5. Prediction: A Stock Market Crash Is Coming. Here's the 1 Growth Stock I'd Buy Anyway.

Source: Nasdaq Market Structure